Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Overview of attention for article published in Journal of Clinical Oncology, September 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 13 X users
patent: 15 patents

wikipedia: 2 Wikipedia pages
f1000: 1 research highlight platform

Readers on

mendeley: 146 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 15 X posts from 13 X users, with an upper bound of 45,251 followers.

@eddpasquier @MSCActions @Institut_cancer @univamu @FondationARC @CanceropolePACA @AssoWAugustine @AssoACCL @Evapourlavie Overlapping AE profiles too; haem tox might limit the dose of combination. Was synergy sufficient that you might hope lower doses w…

Aurora A kinase inhibitor alisertib & DLBCL http://t.co/KibgPFfuCm . Kinase enrichment reagent http://t.co/jms0zAzuYz

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and... http://t.co/x7187Kqjsz

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.